The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,339K data for 617K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

42 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands.EBI
University Of Florence
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.EBI
Philipps-Universit£T Marburg
Targeting integrinsavß3 anda5ß1 with newß-lactam derivatives.EBI
University Of Bologna
Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.EBI
Technische Universit£T M£Nchen
Small Macrocycles As Highly Active Integrin?2?1 Antagonists.EBI
Sanofi R & D
Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).EBI
University Hospital Of Geneva
Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics.EBI
University Of Bologna
Arylsulfonamide pyrimidines as VLA-4 antagonists.EBI
Elan Pharmaceuticals
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.EBI
Technische Universit£T M£Nchen
SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.EBI
Jerini
Discovery of orally available integrin alpha5beta1 antagonists.EBI
Jerini
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.EBI
Merck Research Laboratories
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.EBI
Astrazeneca
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.EBI
Astrazeneca
Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.EBI
Universita Degli Studi Di Bologna
Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.EBI
Millennium Pharmaceuticals
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.EBI
Universit£
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.EBI
3-Dimensional Pharmaceuticals
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.EBI
Genentech
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.EBI
Merck Research Laboratories
Ultrasmall particle of iron oxide--RGD peptidomimetic conjugate: synthesis and characterisation.EBI
Universit£
Multiple N-methylation by a designed approach enhances receptor selectivity.EBI
Technische UniversitäT MüNchen
Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.EBI
Università
Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.EBI
Jerini
Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.EBI
Università
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.EBI
Johnson And Johnson Pharmaceutical Research & Development
Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.EBI
Riken Discovery Research Institute
Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.EBI
Nerviano
Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.EBI
Pharmaceutical Research Institute
Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide.EBI
Kyowa Hakko Kogyo
Nonpeptide RGD antagonists: a novel class of mimetics, the 5,8-disubstituted 1-azabicyclo[5.2.0]nonan-2-one lactam.EBI
University Of Montpellier
Thiophene-based vitronectin receptor antagonists.EBI
Shire Biochem
Design and synthesis of potent and selective inhibitors of integrin VLA-4.EBI
Novartis Institute For Biomedical Research
2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.EBI
Taisho Pharmaceutical
Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.EBI
Celltech Chiroscience
Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.EBI
Biogen
Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.EBI
Dupont Pharmaceuticals
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.EBI
Merck Research Laboratories
Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.EBI
Telios Pharmaceuticals
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.EBI
Merck Research Laboratories
Small molecule inhibitors of integrin alpha2beta1.BDB
University Of Pennsylvania